Univariable and multivariable survival analysis for PFS and OS in 34 patients with adrenocortical carcinomas.
| . | Univariable analysis . | Multivariable analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | PFS . | OS . | PFS . | OS . | ||||
| . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . |
| Parameter (n of patients if different from 34) | ||||||||
| Age (≤50 vs >50 years) | 0.88 (0.33-2.40) | .814 | 0.65 (0.28-1.51) | .314 | ||||
| Symptoms at diagnosis (yes vs no) | 2.44 (0.72-8.30) | .154 | .146 | |||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 6.02 (2.14-16.9) | <.001 | 9.49 (2.89-31.2) | <.001 |
| Resection status (n = 22) (R0 vs R1 vs R2) | 1.77 (1.06-2.95) | .030 | 2.59 (1.25-5.37) | .011 | ||||
| Ki67 index (n = 26) (<10 vs 10-19 vs ≥20) | 2.43 (0.92-6.42) | .074 | 5.54 (0.84-36.6) | .075 | ||||
| S-GRAS score (n = 22) (group 1 vs 2 vs 3 vs 4) | 2.14 (1.10-4.16) | .025 | 7.52 (1.83-30.9) | .005 | ||||
| ccfDNA-based BM1 (0 vs 1 vs 2) | 3.45 (1.49-7.96) | .004 | 6.28 (2.24-17.6) | <.001 | 2.01 (0.67-6.02) | .213 | 2.25 (0.68-7.39) | .183 |
| ccfDNA-based BM2 (0 vs 1 vs 2) | 1.89 (1.05-3.40) | .033 | 2.47 (1.33-4.56) | .004 | 1.71 (0.86-3.38) | .125 | 4.16 (1.86-9.31) | <.001 |
| ccfDNA-based scores—Model 1 | ||||||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 5.51 (2.08-14.6) | <.001 | 5.43 (2.12-13.9) | <.001 |
| ccfDNA-based BM score (positive vs negative) | 2.87 (1.20-6.90) | .018 | 8.24 (2.29-29.7) | .001 | 2.86 (0.95-7.54) | .061 | 8.80 (2.01-38.4) | .004 |
| ccfDNA-based scores—Model 2 | ||||||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 6.10 (2.19-16.9) | <.001 | 7.71 (2.82-21.1) | <.001 |
| ccfDNA-based BM score (0 vs 1 vs 2 vs 3 vs 4) | 1.80 (1.22-2.66) | .003 | 2.37 (1.51-3.71) | <.001 | 1.81 (1.15-2.81) | .009 | 3.39 (1.83-6.29) | <.001 |
| . | Univariable analysis . | Multivariable analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | PFS . | OS . | PFS . | OS . | ||||
| . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . |
| Parameter (n of patients if different from 34) | ||||||||
| Age (≤50 vs >50 years) | 0.88 (0.33-2.40) | .814 | 0.65 (0.28-1.51) | .314 | ||||
| Symptoms at diagnosis (yes vs no) | 2.44 (0.72-8.30) | .154 | .146 | |||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 6.02 (2.14-16.9) | <.001 | 9.49 (2.89-31.2) | <.001 |
| Resection status (n = 22) (R0 vs R1 vs R2) | 1.77 (1.06-2.95) | .030 | 2.59 (1.25-5.37) | .011 | ||||
| Ki67 index (n = 26) (<10 vs 10-19 vs ≥20) | 2.43 (0.92-6.42) | .074 | 5.54 (0.84-36.6) | .075 | ||||
| S-GRAS score (n = 22) (group 1 vs 2 vs 3 vs 4) | 2.14 (1.10-4.16) | .025 | 7.52 (1.83-30.9) | .005 | ||||
| ccfDNA-based BM1 (0 vs 1 vs 2) | 3.45 (1.49-7.96) | .004 | 6.28 (2.24-17.6) | <.001 | 2.01 (0.67-6.02) | .213 | 2.25 (0.68-7.39) | .183 |
| ccfDNA-based BM2 (0 vs 1 vs 2) | 1.89 (1.05-3.40) | .033 | 2.47 (1.33-4.56) | .004 | 1.71 (0.86-3.38) | .125 | 4.16 (1.86-9.31) | <.001 |
| ccfDNA-based scores—Model 1 | ||||||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 5.51 (2.08-14.6) | <.001 | 5.43 (2.12-13.9) | <.001 |
| ccfDNA-based BM score (positive vs negative) | 2.87 (1.20-6.90) | .018 | 8.24 (2.29-29.7) | .001 | 2.86 (0.95-7.54) | .061 | 8.80 (2.01-38.4) | .004 |
| ccfDNA-based scores—Model 2 | ||||||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 6.10 (2.19-16.9) | <.001 | 7.71 (2.82-21.1) | <.001 |
| ccfDNA-based BM score (0 vs 1 vs 2 vs 3 vs 4) | 1.80 (1.22-2.66) | .003 | 2.37 (1.51-3.71) | <.001 | 1.81 (1.15-2.81) | .009 | 3.39 (1.83-6.29) | <.001 |
S-GRAS score was calculated as previously published (Elhassan et al., Eur J Endocrinol 2021, DOI: 10.1530/EJE-21-0510). Significant variables available in all patients are in bold.
Abbreviations: BM, biomarker; BM1, total ccfDNA concentrations; BM2, somatic variants detected in ccfDNA; ccfDNA, circulating cell-free DNA; ENSAT, European Network for the Study of Adrenocortical Tumors; OS, overall survival; PFS, progression-free survival.
Univariable and multivariable survival analysis for PFS and OS in 34 patients with adrenocortical carcinomas.
| . | Univariable analysis . | Multivariable analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | PFS . | OS . | PFS . | OS . | ||||
| . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . |
| Parameter (n of patients if different from 34) | ||||||||
| Age (≤50 vs >50 years) | 0.88 (0.33-2.40) | .814 | 0.65 (0.28-1.51) | .314 | ||||
| Symptoms at diagnosis (yes vs no) | 2.44 (0.72-8.30) | .154 | .146 | |||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 6.02 (2.14-16.9) | <.001 | 9.49 (2.89-31.2) | <.001 |
| Resection status (n = 22) (R0 vs R1 vs R2) | 1.77 (1.06-2.95) | .030 | 2.59 (1.25-5.37) | .011 | ||||
| Ki67 index (n = 26) (<10 vs 10-19 vs ≥20) | 2.43 (0.92-6.42) | .074 | 5.54 (0.84-36.6) | .075 | ||||
| S-GRAS score (n = 22) (group 1 vs 2 vs 3 vs 4) | 2.14 (1.10-4.16) | .025 | 7.52 (1.83-30.9) | .005 | ||||
| ccfDNA-based BM1 (0 vs 1 vs 2) | 3.45 (1.49-7.96) | .004 | 6.28 (2.24-17.6) | <.001 | 2.01 (0.67-6.02) | .213 | 2.25 (0.68-7.39) | .183 |
| ccfDNA-based BM2 (0 vs 1 vs 2) | 1.89 (1.05-3.40) | .033 | 2.47 (1.33-4.56) | .004 | 1.71 (0.86-3.38) | .125 | 4.16 (1.86-9.31) | <.001 |
| ccfDNA-based scores—Model 1 | ||||||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 5.51 (2.08-14.6) | <.001 | 5.43 (2.12-13.9) | <.001 |
| ccfDNA-based BM score (positive vs negative) | 2.87 (1.20-6.90) | .018 | 8.24 (2.29-29.7) | .001 | 2.86 (0.95-7.54) | .061 | 8.80 (2.01-38.4) | .004 |
| ccfDNA-based scores—Model 2 | ||||||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 6.10 (2.19-16.9) | <.001 | 7.71 (2.82-21.1) | <.001 |
| ccfDNA-based BM score (0 vs 1 vs 2 vs 3 vs 4) | 1.80 (1.22-2.66) | .003 | 2.37 (1.51-3.71) | <.001 | 1.81 (1.15-2.81) | .009 | 3.39 (1.83-6.29) | <.001 |
| . | Univariable analysis . | Multivariable analysis . | ||||||
|---|---|---|---|---|---|---|---|---|
| . | PFS . | OS . | PFS . | OS . | ||||
| . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . | HR (95% CI) . | P-value . |
| Parameter (n of patients if different from 34) | ||||||||
| Age (≤50 vs >50 years) | 0.88 (0.33-2.40) | .814 | 0.65 (0.28-1.51) | .314 | ||||
| Symptoms at diagnosis (yes vs no) | 2.44 (0.72-8.30) | .154 | .146 | |||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 6.02 (2.14-16.9) | <.001 | 9.49 (2.89-31.2) | <.001 |
| Resection status (n = 22) (R0 vs R1 vs R2) | 1.77 (1.06-2.95) | .030 | 2.59 (1.25-5.37) | .011 | ||||
| Ki67 index (n = 26) (<10 vs 10-19 vs ≥20) | 2.43 (0.92-6.42) | .074 | 5.54 (0.84-36.6) | .075 | ||||
| S-GRAS score (n = 22) (group 1 vs 2 vs 3 vs 4) | 2.14 (1.10-4.16) | .025 | 7.52 (1.83-30.9) | .005 | ||||
| ccfDNA-based BM1 (0 vs 1 vs 2) | 3.45 (1.49-7.96) | .004 | 6.28 (2.24-17.6) | <.001 | 2.01 (0.67-6.02) | .213 | 2.25 (0.68-7.39) | .183 |
| ccfDNA-based BM2 (0 vs 1 vs 2) | 1.89 (1.05-3.40) | .033 | 2.47 (1.33-4.56) | .004 | 1.71 (0.86-3.38) | .125 | 4.16 (1.86-9.31) | <.001 |
| ccfDNA-based scores—Model 1 | ||||||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 5.51 (2.08-14.6) | <.001 | 5.43 (2.12-13.9) | <.001 |
| ccfDNA-based BM score (positive vs negative) | 2.87 (1.20-6.90) | .018 | 8.24 (2.29-29.7) | .001 | 2.86 (0.95-7.54) | .061 | 8.80 (2.01-38.4) | .004 |
| ccfDNA-based scores—Model 2 | ||||||||
| ENSAT tumour stage (1-2 vs 3 vs 4) | 6.40 (2.34-17.5) | <.001 | 6.60 (2.51-17.3) | <.001 | 6.10 (2.19-16.9) | <.001 | 7.71 (2.82-21.1) | <.001 |
| ccfDNA-based BM score (0 vs 1 vs 2 vs 3 vs 4) | 1.80 (1.22-2.66) | .003 | 2.37 (1.51-3.71) | <.001 | 1.81 (1.15-2.81) | .009 | 3.39 (1.83-6.29) | <.001 |
S-GRAS score was calculated as previously published (Elhassan et al., Eur J Endocrinol 2021, DOI: 10.1530/EJE-21-0510). Significant variables available in all patients are in bold.
Abbreviations: BM, biomarker; BM1, total ccfDNA concentrations; BM2, somatic variants detected in ccfDNA; ccfDNA, circulating cell-free DNA; ENSAT, European Network for the Study of Adrenocortical Tumors; OS, overall survival; PFS, progression-free survival.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
